Application 018817

Type
NDA
Sponsor
GD SEARLE LLC

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001CALANVERAPAMIL HYDROCHLORIDETABLET;ORAL80MGYesNo
002CALANVERAPAMIL HYDROCHLORIDETABLET;ORAL120MGYesNo
003CALANVERAPAMIL HYDROCHLORIDETABLET;ORAL40MGNoNo
004CALANVERAPAMIL HYDROCHLORIDETABLET;ORAL160MGNoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0025-1861CALANverapamil hydrochlorideG.D. Searle LLC Division of Pfizer IncNDACurrent
0025-1861CALANverapamil hydrochlorideG.D. Searle LLC Division of Pfizer IncNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
71184SUPPL2022-06-01
69376SUPPL2021-11-23
49801SUPPL2017-09-19
49760SUPPL2017-09-18
45235SUPPL2016-08-24
33613SUPPL2013-10-31
16060SUPPL2013-10-28
1095SUPPL2011-11-07
33612SUPPL2011-11-04
1094SUPPL2011-07-05
33611SUPPL2011-06-30
33610SUPPL2010-04-19
1093SUPPL2010-04-19
33609SUPPL2009-07-23
16059SUPPL2009-07-17